Home›Stock Screener›Vivo Bio Tech›Fair Value

Vivo Bio Tech Fair Value

Average Fair Value
₹35.28
Current Market Price: ₹26.32
+34.05% Price Difference

Vivo Bio Tech (VIVOBIOT) average fair value is ₹35.28 across 8 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹26.32 (+34.05%), fair value range ₹1.16–₹119.52. See VIVOBIOT book value to compare market price against book value per share.

Fair Value Analysis Export

VIVOBIOT Fair Value vs Current Price — Valuation Summary

VIVOBIOT average fair value, fair value range, price gap and valuation status across 8 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit VIVOBIOT share price screener.

Average Fair Value
₹35.28
Current Market Price
₹26.32
Price Difference
₹8.96
Percentage Difference
+34.05%
Fair Value Range
₹1.16 - ₹119.52
Methods Used
8
Analysis based on 8 valuation methods: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF)

P/E Based Valuation

Current EPS ₹0.45
Sector Avg P/E 18.73
Historical Avg P/E N/A
Average Fair Value
₹8.06

P/B Based Valuation

Book Value/Share ₹45.88
Sector Avg P/B 3.71
Historical Avg P/B N/A
Average Fair Value
₹119.52

Price-to-Sales Valuation

Revenue/Share ₹5.66
Sector Avg P/S 4.0
Fair Value
₹22.63

Asset-Based Valuation

Book Value/Share ₹45.88
Liquidation Value/Share ₹58.88
Fair Value
₹45.88

Earnings Growth Model (PEG)

Current EPS ₹0.45
Growth Rate 2.59%
Fair P/E Ratio 2.59
Fair Value
₹1.16

Peter Lynch Fair Value

Current EPS ₹2.44
Growth Rate 2.59%
Dividend Yield 0%
Lynch Factor 2.59
Fair P/E Ratio 2.59
Data Source Quarterly Data (7 years)
Fair Value (Lynch Factor Adjusted)
₹6.31

Benjamin Graham Number

Current EPS ₹0.45
Book Value/Share ₹45.88
Graham Multiplier 22.5
Current P/E 13.26
Graham Criteria 2/3
Graham Number
₹21.55
Criteria Met: P/E ≤ 15, P/B ≤ 1.5

Discounted Cash Flow (DCF)

Current FCF ₹12.0 Cr
FCF Growth Rate -3.78%
Discount Rate 10.0%
Terminal Growth 3.0%
Enterprise Value ₹131.3 Cr
DCF Fair Value
₹57.15

VIVOBIOT Fair Value Analysis — Data Sources & Coverage

Vivo Bio Tech financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. Examine VIVOBIOT earnings for recent quarterly revenue, profit and EPS trends.

Methods Used
8
Data Year
2025
Sector
Healthcare

Available Data Sources: Financial statements, balance sheet data , sector comparisons.

Data Currency: Financial data is from the previous year (2025).

VIVOBIOT vs Healthcare Sector Peers — P/E, P/B & Market Cap

Vivo Bio Tech P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.

Company Symbol P/E Ratio P/B Ratio Market Cap (₹ Cr)
Murae Organisor MURAE 2.86 0.2 ₹41
Accretion Pharmaceuticals ACCPL 17.91 2.7 ₹120
Jeena Sikho Lifecare JSLL 40.38 23.07 ₹7,944
Par Drugs & Chemical PAR 8.2 0.96 ₹103
Aurobindo Pharma AUROPHARMA 25.16 2.5 ₹87,806

Important Disclaimer

This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.

This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.

Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.